Event Timeline
| 05:45 PM - 05:51 PM CDT |
Speaker |
A Pivotal, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of N-acetylmannosamine (ManNAc) in GNE myopathy: Results from the NN109 MAGiNE Study
|
| 05:51 PM - 05:57 PM CDT |
Speaker |
Efficacy and Safety Results of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Latozinemab (AL001) in FTD-GRN
|
| 05:57 PM - 06:03 PM CDT |
Speaker |
Deramiocel Significantly Slows Upper Limb Functional Decline in Duchenne Muscular Dystrophy: Skeletal Muscle Outcomes from the Phase 3 HOPE-3 Trial
|
| 06:03 PM - 06:09 PM CDT |
Speaker |
Characterization of "Early-Start" Participants that Continued Receiving Donanemab in the TRAILBLAZER-ALZ 2 Long-Term Extension Period
|
| 06:09 PM - 06:15 PM CDT |
Speaker |
Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies
|
| 06:15 PM - 06:21 PM CDT |
Speaker |
Efficacy and Safety of Crisugabalin in Patients With Moderate-to-Severe Central Neuropathic Pain: A Phase 3 Randomized Clinical Trial
|
| 06:21 PM - 06:27 PM CDT |
Speaker |
ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale
|
| 06:27 PM - 06:33 PM CDT |
Speaker |
Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8)
|
| 06:33 PM - 06:39 PM CDT |
Speaker |
Breastfeeding and Subsequent Neuropsychological Outcomes at Age 6-Years-Old in the MONEAD Study
|
| 06:39 PM - 07:00 PM CDT |
Q&A |
Poster Q&A
|